Latest Ratios: P/E Ratio 32.8x · EV/EBITDA 15.4x · ROE 10.4%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13.3B | $11.3B | $15.6B | $21.0B | $16.5B | $52.4B | $42.3B | $22.4B | $17.0B | $18.2B | $7.8B |
| Enterprise Value | $12.3B | $10.4B | $14.7B | $20.2B | $15.7B | $51.4B | $41.5B | $21.9B | $16.4B | $17.7B | $7.4B |
| P/E Ratio → | 32.78 | 27.64 | 37.10 | 47.16 | 45.75 | 67.82 | 23.85 | 50.46 | 42.57 | 78.51 | 41.26 |
| P/S Ratio | 3.29 | 2.81 | 3.91 | 5.43 | 4.43 | 13.25 | 17.13 | 9.29 | 8.66 | 12.34 | 7.25 |
| P/B Ratio | 3.32 | 2.80 | 4.06 | 5.78 | 4.59 | 14.45 | 13.09 | 16.60 | 13.60 | 15.81 | 7.87 |
| P/FCF | 27.03 | 23.10 | 25.11 | 34.50 | 59.74 | 67.87 | 83.47 | 37.40 | 51.42 | 74.87 | 44.24 |
| P/OCF | 22.36 | 19.11 | 21.18 | 26.70 | 29.08 | 44.65 | 63.94 | 29.91 | 30.72 | 41.46 | 31.63 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.57 | 3.68 | 5.22 | 4.21 | 13.00 | 16.77 | 9.08 | 8.34 | 12.04 | 6.89 |
| EV / EBITDA | 15.44 | 13.01 | 19.55 | 25.67 | 20.46 | 47.35 | 86.26 | 35.17 | 31.46 | 45.31 | 27.27 |
| EV / EBIT | 19.96 | 17.72 | 21.90 | 30.71 | 24.04 | 52.63 | 107.10 | 42.49 | 35.15 | 50.15 | 29.90 |
| EV / FCF | — | 21.13 | 23.63 | 33.17 | 56.80 | 66.61 | 81.74 | 36.58 | 49.50 | 73.02 | 42.04 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.3% | 68.3% | 70.0% | 70.1% | 70.5% | 74.3% | 71.3% | 72.5% | 73.6% | 75.8% | 75.5% |
| Operating Margin | 15.3% | 15.3% | 15.2% | 16.7% | 17.2% | 24.7% | 15.7% | 22.5% | 23.7% | 24.0% | 23.1% |
| Net Profit Margin | 10.2% | 10.2% | 10.5% | 11.5% | 9.7% | 19.5% | 71.8% | 18.4% | 20.4% | 15.7% | 17.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.4% | 10.4% | 11.3% | 12.3% | 10.0% | 22.5% | 77.5% | 34.1% | 33.3% | 21.6% | 20.6% |
| ROA | 6.6% | 6.6% | 6.9% | 7.4% | 6.1% | 14.3% | 48.5% | 19.4% | 20.9% | 14.6% | 14.8% |
| ROIC | 15.4% | 15.4% | 15.9% | 17.2% | 17.7% | 29.2% | 18.1% | 55.3% | 53.1% | 40.6% | 29.0% |
| ROCE | 14.5% | 14.5% | 14.8% | 16.0% | 16.0% | 26.0% | 15.4% | 37.5% | 35.3% | 30.5% | 25.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | — | — | — |
| Debt / EBITDA | 0.14 | 0.14 | 0.16 | 0.16 | 0.17 | 0.12 | 0.18 | 0.10 | — | — | — |
| Net Debt / Equity | — | -0.24 | -0.24 | -0.22 | -0.23 | -0.27 | -0.27 | -0.36 | -0.51 | -0.39 | -0.39 |
| Net Debt / EBITDA | -1.21 | -1.21 | -1.23 | -1.03 | -1.06 | -0.90 | -1.82 | -0.79 | -1.22 | -1.15 | -1.43 |
| Debt / FCF | — | -1.97 | -1.48 | -1.33 | -2.94 | -1.26 | -1.72 | -0.82 | -1.92 | -1.85 | -2.20 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($1.1B) exceeds total debt ($114M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | 1.36 | 1.22 | 1.18 | 1.26 | 1.30 | 1.40 | 1.68 | 1.88 | 2.32 | 2.69 |
| Quick Ratio | 1.24 | 1.24 | 1.10 | 1.04 | 1.08 | 1.18 | 1.29 | 1.57 | 1.80 | 2.26 | 2.61 |
| Cash Ratio | 0.57 | 0.57 | 0.51 | 0.47 | 0.52 | 0.61 | 0.72 | 0.89 | 1.06 | 1.45 | 1.81 |
| Asset Turnover | — | 0.65 | 0.64 | 0.63 | 0.63 | 0.67 | 0.51 | 0.96 | 0.96 | 0.83 | 0.77 |
| Inventory Turnover | 5.65 | 5.65 | 4.72 | 3.89 | 3.25 | 4.42 | 5.09 | 5.92 | 9.32 | 11.25 | 9.75 |
| Days Sales Outstanding | — | 104.71 | 93.98 | 98.96 | 97.75 | 91.50 | 97.11 | 93.50 | 89.52 | 80.31 | 83.63 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.1% | 3.6% | 2.7% | 2.1% | 2.2% | 1.5% | 4.2% | 2.0% | 2.3% | 1.3% | 2.4% |
| FCF Yield | 3.7% | 4.3% | 4.0% | 2.9% | 1.7% | 1.5% | 1.2% | 2.7% | 1.9% | 1.3% | 2.3% |
| Buyback Yield | 3.5% | 4.1% | 2.3% | 2.8% | 2.6% | 0.7% | 0.0% | 1.8% | 1.8% | 0.6% | 1.2% |
| Total Shareholder Yield | 3.5% | 4.1% | 2.3% | 2.8% | 2.6% | 0.7% | 0.0% | 1.8% | 1.8% | 0.6% | 1.2% |
| Shares Outstanding | — | $73M | $75M | $77M | $78M | $80M | $79M | $80M | $81M | $82M | $81M |
Macro-driven elective demand volatility
Based on current market data, Align Technology trades at a forward P/E of 15.69, a significant compression from its historical premiums, suggesting that investors are increasingly pricing the company as a mature medical device manufacturer rather than a high-growth disruptor in the digital dentistry space.
The current valuation multiples appear to account for the stagnation in top-line growth, as the market no longer assigns a high-growth PEG premium to the stock. This shift warrants caution, as the current P/S of 3.17 may still be vulnerable if the company fails to reignite volume growth through its iTero ecosystem.
According to recent quarterly filings, Align Technology's ROIC has trended downward to 4.1% in 2026Q1, a notable decline from historical levels that indicates the company is struggling to generate superior returns on its invested capital as competitive pressures and market saturation intensify.
The compression in ROIC suggests that the capital-intensive nature of maintaining a global manufacturing and R&D footprint is yielding diminishing marginal returns. Investors should monitor whether management can optimize its asset base or if the current capital allocation strategy is failing to drive meaningful value creation.
As reported in the financial statements, Align Technology's cash conversion cycle remains elevated at 128 days in 2026Q1, primarily driven by persistent DSO levels near 100 days, which highlights potential inefficiencies in collecting payments from its professional customer base across diverse global markets.
The extended CCC suggests that the company is effectively financing its customers' operations, which may be a strategic necessity to maintain market share but creates a drag on liquidity. This inefficiency appears structural and may limit the company's ability to self-fund growth without relying on its existing cash reserves.
Based on the reported figures, Align Technology maintains a current ratio of 1.39, providing a stable liquidity cushion that appears sufficient to navigate the current period of stagnant revenue growth and potential volatility in elective procedure demand without requiring external debt financing.
The company's liquidity position remains healthy, supported by a conservative debt-to-equity ratio of 0.03. While this provides a fortress-like balance sheet, the lack of significant debt service obligations also means the company lacks the discipline of leverage, potentially allowing for inefficient capital allocation during periods of low growth.
The most commonly misapplied metric for Align Technology is the trailing P/E ratio, which frequently obscures the impact of significant stock-based compensation and non-recurring items that distort the company's true earnings power and cash-generating capacity in a maturing, cyclical medical device market.
Analysts should instead focus on free cash flow yield or EV/EBITDA, as these metrics better account for the company's high capital expenditure requirements and the non-cash nature of its compensation expenses. Relying on P/E alone may lead to an inaccurate assessment of the company's valuation relative to its peers.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALGN stock.
Align Technology, Inc.'s current P/E ratio is 32.8x. The historical average is 42.6x. This places it at the 32th percentile of its historical range.
Align Technology, Inc.'s current EV/EBITDA is 15.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 28.8x.
Align Technology, Inc.'s return on equity (ROE) is 10.4%. The historical average is 11.2%.
Based on historical data, Align Technology, Inc. is trading at a P/E of 32.8x. This is at the 32th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Align Technology, Inc. has 68.3% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.
Align Technology, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.